Marcy l’Etoile, France - April 24, 2012.
First-Quarter 2012 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the three months ended March 31, 2012.
Sales up 9.3% at constant exchange rates
- Of which 3.1% organic growth, in line with objectives
- Strong momentum* in China (up 47%) and India (up 31%)
- Solid performance* in industrial applications (up 11.6%)
Significant operational advances
2012 sales growth objective confirmed
Net sales for the period amounted to €363 million, versus €328 million in first-quarter 2011, representing an increase of 9.3% at constant exchange rates. Organic growth amounted to 3.1%, at constant exchange rates and comparable business base**.
Download a PDF of the Full Report
* At constant exchange rates and comparable business base
** Excluding the acquisition of AES Laboratoire and ARGENE, the divestiture of Dima Diagnostika and the discontinuation of culture media business for routine clinical tests in North America